science

Newly Discovered Protein Impedes Effectiveness of CAR T-Cell Therapy

2 Haziran 2026Science Daily

A newly identified protein, NFIL3, has been found to significantly hinder the effectiveness of CAR T-cell therapy in cancer treatment. Researchers discovered that NFIL3 leads to the exhaustion of these engineered immune cells, diminishing their cancer-fighting capabilities over time.
However, disabling NFIL3 resulted in stronger, more effective tumor control in animal models.
CAR T-cell therapy has revolutionized cancer treatment by harnessing the body's immune system to fight tumors. However, challenges such as immune cell exhaustion have limited its long-term effectiveness.
The discovery of NFIL3 as a limiting factor in CAR T-cell therapy highlights a critical area for further research and potential therapeutic intervention. By targeting this protein, scientists may enhance the longevity and efficacy of CAR T-cells, offering new hope for patients with resistant cancers.

NewsAI özeti

This summary is based on research findings and should not be considered medical advice.

Tam teknik rapor ve canlı veriler için yayıncının web sitesini ziyaret edin.

Her yerde okuyun. iOS ve Android için ödüllü uygulamalarımızı indirin.